These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 23182164)

  • 1. Predictive factors for an uncomplicated long-term course of Crohn's disease: a retrospective analysis.
    Kruis W; Katalinic A; Klugmann T; Franke GR; Weismüller J; Leifeld L; Ceplis-Kastner S; Reimers B; Bokemeyer B
    J Crohns Colitis; 2013 Aug; 7(7):e263-70. PubMed ID: 23182164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial.
    Reinisch W; Angelberger S; Petritsch W; Shonova O; Lukas M; Bar-Meir S; Teml A; Schaeffeler E; Schwab M; Dilger K; Greinwald R; Mueller R; Stange EF; Herrlinger KR;
    Gut; 2010 Jun; 59(6):752-9. PubMed ID: 20551460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.
    Sandborn WJ; Colombel JF; Panés J; Castillo M; Robinson AM; Zhou Q; Yang M; Thakkar R
    J Crohns Colitis; 2013 Dec; 7(12):958-67. PubMed ID: 23517933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pediatric Crohn's disease activity at diagnosis, its influence on pediatrician's prescribing behavior, and clinical outcome 5 years later.
    Mesker T; van Rheenen PF; Norbruis OF; Uitentuis J; Waalkens HJ; Gonera G; van Overbeek LA; Butler J; Rings EH
    Inflamm Bowel Dis; 2009 Nov; 15(11):1670-7. PubMed ID: 19418567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease Phenotype, Activity and Clinical Course Prediction Based on C-Reactive Protein Levels at Diagnosis in Patients with Crohn's Disease: Results from the CONNECT Study.
    Kwon JH; Im JP; Ye BD; Cheon JH; Jang HJ; Lee KM; Kim YS; Kim SW; Kim YH; Song GA; Han DS; Kim WH; Kim JS
    Gut Liver; 2016 Jul; 10(4):595-603. PubMed ID: 27021506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mild-to-moderate active luminal Crohn's disease.
    Michetti P; Juillerat P; Mottet C; Pittet V; Gonvers JJ; Vader JP; Froehlich F; Felley C
    Digestion; 2007; 76(2):92-8. PubMed ID: 18239399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
    Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
    Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
    Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
    Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
    Burisch J
    Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term course of Crohn's disease in Japan: Incidence of complications, cumulative rate of initial surgery, and risk factors at diagnosis for initial surgery.
    Sato Y; Matsui T; Yano Y; Tsurumi K; Okado Y; Matsushima Y; Koga A; Takahashi H; Ninomiya K; Ono Y; Takatsu N; Beppu T; Nagahama T; Hisabe T; Takaki Y; Hirai F; Yao K; Higashi D; Futami K; Washio M
    J Gastroenterol Hepatol; 2015 Dec; 30(12):1713-9. PubMed ID: 26094852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
    Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E;
    Am J Gastroenterol; 2002 Mar; 97(3):649-53. PubMed ID: 11922560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum calprotectin as a biomarker for Crohn's disease.
    Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
    J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural History of Crohn's Disease in Elderly Patients Diagnosed Over the Age of 70 Years: A Population-Based Study.
    Fumery M; Pariente B; Sarter H; Charpentier C; Armengol Debeir L; Dupas JL; Coevoet H; Peyrin-Biroulet L; dʼAgay L; Gower-Rousseau C; Savoye G;
    Inflamm Bowel Dis; 2016 Jul; 22(7):1698-707. PubMed ID: 27206018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
    Feagan BG; Sandborn WJ
    Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mesalazine and sulphasalazine for Crohn's disease: few indications, severe adverse reactions].
    Uittenbogaart SB; Klemt-Kropp M
    Ned Tijdschr Geneeskd; 2011; 155(48):A3842. PubMed ID: 22152414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project.
    Cleynen I; González JR; Figueroa C; Franke A; McGovern D; Bortlík M; Crusius BJ; Vecchi M; Artieda M; Szczypiorska M; Bethge J; Arteta D; Ayala E; Danese S; van Hogezand RA; Panés J; Peña SA; Lukas M; Jewell DP; Schreiber S; Vermeire S; Sans M
    Gut; 2013 Nov; 62(11):1556-65. PubMed ID: 23263249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective population-based cohort of inflammatory bowel disease in the biologics era: Disease course and predictors of severity.
    Niewiadomski O; Studd C; Hair C; Wilson J; Ding NS; Heerasing N; Ting A; McNeill J; Knight R; Santamaria J; Prewett E; Dabkowski P; Dowling D; Alexander S; Allen B; Popp B; Connell W; Desmond P; Bell S
    J Gastroenterol Hepatol; 2015 Sep; 30(9):1346-53. PubMed ID: 25867770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of enterocutaneous fistula in patients with Crohn's disease treated with anti-TNF therapy: a cohort study from the GETAID.
    Amiot A; Setakhr V; Seksik P; Allez M; Treton X; De Vos M; Laharie D; Colombel JF; Abitbol V; Reimund JM; Moreau J; Veyrac M; Flourié B; Cosnes J; Lemann M; Bouhnik Y
    Am J Gastroenterol; 2014 Sep; 109(9):1443-9. PubMed ID: 25091063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lewis Score--Prognostic Value in Patients with Isolated Small Bowel Crohn's Disease.
    Dias de Castro F; Boal Carvalho P; Monteiro S; Rosa B; Firmino-Machado J; Moreira MJ; Cotter J
    J Crohns Colitis; 2015 Dec; 9(12):1146-51. PubMed ID: 26377028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low predictive value of histopathological scoring system for complications development in children with Crohn's disease.
    Fabian O; Hradsky O; Potuznikova K; Kalfusova A; Krskova L; Hornofova L; Zamecnik J; Bronsky J
    Pathol Res Pract; 2017 Apr; 213(4):353-358. PubMed ID: 28216137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.